MT Auburn Hospital Mammograms What To Expect

HOLOGIC, INC.

DGAP-News: Izotropic Corporation / Key word (s): Miscellaneous Tomosynthesis Pioneer Joins Izotropic's Scientific Advisory Board 2021-04-20 / 20:41 The issuer is responsible for the content of this announcement. = ------------------------------------------------- -------------------------------------------------- ------------------- Vancouver, British Columbia - (Newsfile Corp. - Tuesday, April 20, 2021) - The Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF ) (FSE: 1R3) ("Izotropic" or the "Company"), a company that markets true 3D breast CT imaging technology for the early detection of breast cancer, has placed an order for Dr. Tao Wu known in its scientific advisory board. Dr. John McGraw, President and CEO of Izotropic, commented, "I am delighted to welcome Dr. Wu to our advisory board. He is a pioneer in digital breast tomosynthesis (DBT) at Harvard Medical School, Massachusetts General Hospital ( MGH) and was later involved in the development and marketing of DBT and FFDM (Full Field Digital Mammography) products. Dr. Wu's extensive experience in development, manufacture and marketing reinforces our efforts to bring these established technologies through IzoView replace our breast CT imaging machine for significantly improved breast cancer diagnosis. " Dr. Wu stated, "I am very honored and excited to be part of an impressive advisory board and support an experienced product team that I have known for over 20 years. I am closely involved with DBT, from early engineering to clinical Proof to subsequent product development and commercialization. I see IzoView and its founders as leaders in breast CT and am excited to bring my experience in promoting breast CT for higher quality breast health care. Together we will in the US and fight against breast cancer worldwide. " Dr. Wu's career: Dr. Wu received his bachelor's degree in physics from Beijing University. As a PhD student at Brandeis University, he worked with Dr. Daniel Kopans of MGH on developing the world's first DBT prototype and demonstrating its technical and clinical benefits through clinical studies. He then joined Hologic as a senior medical physicist to develop commercial DBT and FFDM products. He later promoted DBT in the Asia-Pacific region on behalf of Hologic and managed business operations in China. After leaving Hologic, Dr. Wu DART Imaging in China. Dr. Wu has received the following honors, among others:. 2003: Young Investigator Award from the American Association of Physicists in Medicine (AAPM). 2004: AAPM Sylvia Sorkin Greenfield Award for best contribution published in Medical Physics. 2011: Serenity Award from Hologic for successfully developing FFDM in China and obtaining CFDA approval. . 2019: German Red Dot Award for the design of the DBT product "Soleil" with the DART imaging team. Dr. Wu was also a member of the AAPM Mammography Subcommittee, Tomosynthesis Working Group, and participated in the development of the national standard for FFDM quality control in China. ON BEHALF OF THE BOARD For investor relations inquiries, please contact: James Berard Email: [email protected] Mobile Phone: 778-228-2314 Toll Free: 1-833-IZOCORP Extension 1 About Izotropic Corporation The Izotropic Corporation markets a specialized breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. Extensive preliminary studies have shown that breast CT may routinely detect small breast tumors ranging in size from 3 to 5 mm. The average size of breast cancer ulcers determined by mammography is approximately 11 mm. With routine detection of 3 mm lesions, breast cancer could be detected 1.5 years earlier than mammography. The first indication to use breast CT as a diagnostic device was confirmed. Upcoming business goals include identifying additional indications for use and developing accessories and additional products, all with the aim of making breast CT an indispensable tool for better breast cancer management. For more information about Izotropic Corporation, please visit their website at izocorp.com and their profile on SEDAR at sedar.com. Forward-Looking Statements This document may contain "forward-looking statements" based on current estimates, assumptions, forecasts and expectations of management, business and knowledge of the relevant market and economic environment of the company. The company has attempted to use terms such as "anticipate," "believe," "imagine," "estimate," "anticipate," "anticipate," "anticipate," "expect" such information and statements in connection with any discussion of future events, trends or prospects or future operational or financial performance "," intend "," maybe "," plan "," predict "," project "," aim "," potential "," will "," would "," could "," should "," continue ", to identify "consider" and other similar expressions and derivatives thereof. However, not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict. These could mean that future results of the company's business activities differ materially from the content and effects of such statements. Forward-looking statements only apply at the time of their publication. The company undertakes no obligation to update or change any forward-looking statements to reflect new information or the occurrence of future events or circumstances, unless otherwise required by law. Neither the company nor its shareholders, officers and consultants are liable for any action or the results thereof, which may be taken by any person based on the information contained herein, in particular the purchase or sale of any securities of the company. Nothing in this document should be taken as medical or other advice of any kind. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81062 Click on, or paste the following link into your web browser, to view the associated documents http: // www.newsfilecorp .com / release / 81062 News Source: Newsfile = --------------------------------------- -------------------------------------------------- ----------------------------- 2021-04-20 Publication of a Corporate News / Financial News, transmitted by DGAP - a service of the EQS Group AG. The issuer is responsible for the content of the announcement. DGAP Distribution Services include regulatory reporting, corporate / financial news, and press releases. Media archive at http://www.dgap.de = -------------------------------------- -------------------------------------------------- ------------------------------ Language: German Company: Izotropic Corporation Canada ISIN: CA46604F1099 EQS News ID: 1186886 End of Announcement DGAP News service = ------------

1186886 2021-04-20

Image link: https% 3a% 2f% 2fwww.newsfilecorp.com% 2fnewsinfo% 2f81062% 2f169 Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1186886&application_name=news

(END) Dow Jones Newswires

April 20, 2021 2:42 PM ET (6:42 PM GMT)